Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261260 · ClinicalTrials.gov registry record · Phase 1
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
A Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01261260 is a Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 33 participants.
The verdict
NCT01261260, a Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those indicating GABA-ergic effects following 14 day pyrimidine administration, the purpose of this study is to assess our following hypotheses: 1. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males; 2. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase NTP levels in a sample of healthy, unmedicated adult males; and 3. Brain GABA levels will be directly correlated to high energy phosphate levels in this sample of healthy, unmedicated adult males.
Interventions
- DRUG Uridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261260
The ClinicalTrials.gov registry entry for NCT01261260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Uridine is the first listed.
NCT01261260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01261260 about?
NCT01261260 is a clinical study titled "Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers". On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those indicating GABA-ergic effects following 14 day pyrimidine administration, the purpose of this study is to assess our following hypotheses: 1. Relative to placebo, an...
What is the current status of trial NCT01261260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT01261260?
The interventions under investigation include: Uridine (DRUG).
Who is sponsoring clinical trial NCT01261260?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.